Navigation Links
Study reveals possible link between IBD therapy and skin cancer
Date:10/29/2009

San Diego, CA (October 26, 2009) Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

Dr. Millie Long, of the University of North Carolina, Chapel Hill, and her colleagues examined the records of 26,403 patients with Crohn's disease and 26,974 patients with ulcerative colitis, dating from 1996 through 2005. The researchers investigated whether IBD could be associated with a higher risk of NMSC and whether the risk of NMSC increased as a result of immunosuppressive and biologic medications. Each IBD patient in the cohort study was matched according to age, gender and region of the country with three randomly selected control patient records who did not have Crohn's disease or ulcerative colitis. In addition, in a nested case-control study, 387 patients with Crohn's disease and NMSC and 355 patients with ulcerative colitis and NMSC were matched on age, gender and region of the country with four random control patients with Crohn's disease or ulcerative colitis who did not have NMSC to evaluate the impact of immunosuppressive and biologic medications on NMSC risk. According to the study findings, the incidence rate ratio (IRR) of NMSC was higher in patients with IBD compared to their matched controls (IRR: 1.64). In addition, recent use of any immunosuppressive medication (within 90 days) was associated with greater risk of NMSC (adjusted Odds Ratio (OR) 3.28), as was recent use of the thiopurine class of immunosuppressive medications (adjusted OR 3.56) and recent use of biologic medications in patients with Crohn's disease (adjusted OR 2.07).

Persistent use of any immunosuppressive medication (>365 days) was strongly associated with NMSC (adjusted OR 4.04). In particular, persistent use of the thiopurine class was strongly associated with NMSC (adjusted OR 4.27). Persistent use of biologic medications in patients with Crohn's disease was also associated with NMSC (adjusted OR 2.18).

"The increased risk of NMSC in patients with IBD is likely related to the immunosuppressive medications used to treat the disease, although we can't rule out changes to the immune system itself as a result of IBD as contributing to this risk," explains Dr. Long who led the study. "In patients on immunosuppression therapy after organ transplant, previous studies have shown a clear association with NMSC. Other studies have demonstrated that azathioprine, which is in the thiopurine class, can increase the photosensitization of human skin."

"Our study demonstrates that patients with IBD on immunosupression may also be at risk for NMSC. As a result, our long term management plans for IBD patients should stress the daily use of broad-spectrum sunscreen and increased awareness of NMSC to help to prevent complications," concludes Dr. Long.


'/>"/>

Contact: Jennifer Burke Labriola
burkepr@gmail.com
203-405-1479
American College of Gastroenterology
Source:Eurekalert

Related medicine news :

1. New EPA Rodent Study Finds No Low-Dose BPA Effects on Reproductive Function or Behavior
2. U-M study uncovers key to how triggering event in cancer occurs
3. Finding Ways for Disabled People to Participate in Research is Goal of Case Western Reserve University Nursing School Study
4. Pitt study shows linkage between teen girls weight and sexual behavior
5. Diet, Exercise Thwart Diabetes: Study
6. Beaumont, U-M Open Study of Drug for Advanced Breast Cancer
7. Let Kids Sleep Late on Weekends to Fight Fat: Study
8. NeoVista Presents Interim Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
9. Old, New Pap Methods Equally Good, Dutch Study Finds
10. Stanford study recommends change in treating pulmonary embolisms
11. Deadly stomach infection rising in community settings, Mayo Clinic study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... measurement of corrosive ions found in power plant water and steam. , Chlorides ... as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... offered by the American Association of Integrative Medicine and available for application on ... at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco ... blog post about women’s hair loss. Although hair transplant procedures can be seen as ... Menopause or genetics can be two reasons a woman may see her hair thinning. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Israel , March 27, 2017 ... THXBY), a specialty clinical-stage pharmaceutical company specializing in the development ... its public offering in the United ... (ADSs), each ADS representing 40 ordinary shares of ... ADS. In addition, Therapix has granted the underwriters ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in 2017, estimates ... generate $655 million in taxes on retail sales. Out of this ... Washington State,s 37% cannabis retail tax rate. ... that are applied on all retail sales. By 2020, tax revenues ...
Breaking Medicine Technology: